Tom Powles, Professor at the University of London, shared a post on X:
“Data exploring SABR in renal cancer to delay systemic therapy in selected patient looks promising and is being used. Brian Rini highlights the pateint selections means good outcomes will occur with surveillance. Randomisation with OS should be the endpoints . Trials awaited.”
